ndometrial cancer is the most common gynecological malignancy in the United States, with its incidence increasing because of rising obesity rates. 1 Lymph node status is the most important predictor of survival and also guides postoperative treatment planning. 2 Whereas evaluation of lymph nodes has been included in surgical staging criteria for endometrial cancer since 1988, the optimal procedure for lymph node assessment is controversial. Performance of pelvic and paraaortic lymphadenectomy (LND) has been associated with improved survival in cohort studies, but 2 randomized controlled trials demonstrated no impact on survival. 3, 4 For high-grade histologies of endometrial cancer, LND remains relevant, given the greater risk of nodal involvement and recurrence associated with these histologies. 4 However, because there are risks of lymphedema and intraoperative complications associated with LND, many gynecological oncologists omit LND in select patients with endometrial cancer. 5 Sentinel lymph node (SLN) mapping has been proposed as a technique to identify lymph node metastases while reducing the surgical morbidity associated with complete LND. 6 An SLN is defined as the first node to receive drainage from a primary tumor and is the most likely to harbor metastases in cancers with lymphatic spread. SLN mapping may also detect aberrant lymphatic drainage that would be missed on routine LND. SLN mapping is established as the standard of care for the staging of breast cancer and melanoma among other cancers. 7, 8 However, adapting its use in endometrial cancer has been more challenging, given the complexity and bilaterality of the nodal basins that drain the uterus.
Whereas early results for SLN mapping in endometrial cancer were promising, other research has raised concerns about the adequacy of nodal detection, especially for paraaortic nodes. 9, 10 Moreover, body mass index (BMI) may limit the lymphatic spread of tracers used in SLN mapping, which could limit its efficacy in endometrial cancer. 11, 12 For these reasons, current guidelines do not yet recommend SLN mapping as the standard of care in the staging of this malignancy, although national societies and organizations that define treatment standards are increasingly recognizing the utility of this staging approach. For instance, the National Comprehensive Cancer Network states that "selected patients with apparent uterine-confined endometrial carcinoma may be candidates for sentinel lymph node mapping . the expertise of the surgeon and attention to technical detail is critical." 13 Nonetheless, the last meta-analysis of SLN mapping outcomes in endometrial cancer was conducted in 2012.
14 Since that time, numerous studies have been published, demonstrating major advances in SLN technology and techniques. 15 A contemporary understanding of SLN detection rates and technique limitations is critical to advancing surgical staging standards and optimizing mapping in this setting. Thus, the objectives of this systematic review and meta-analysis are as follows: (1) to evaluate the diagnostic accuracy of SLN mapping for the staging of endometrial cancer, (2) to analyze factors associated with the diagnostic accuracy of SLN mapping, and (3) to assess the clinical impact of SLN detection in the management of endometrial cancer.
Materials and Methods

Search strategy
We searched Medline, Embase, and the Cochrane Library from database inception to March 25, 2016. Electronic searches were supplemented by reviewing reference lists of included studies and prior systematic reviews, hand-searching the journal Gynecologic Oncology, and contacting the authors of included studies for any additional published or unpublished studies meeting review inclusion criteria. When the search strategy identified a meeting abstract, we searched Medline for an associated fulltext article by the same author group. We developed search terms based on prior systematic reviews and input from a reference librarian (Table 1) . We limited articles to English language only.
Details of the review protocol were registered on PROSPERO, an international database of prospectively registered systematic reviews, and can be accessed at http://www.crd.york. ac.uk/PROSPERO/display_record.asp? ID¼CRD42016036503.
Inclusion/exclusion criteria Studies were included if they had the following criteria: (1) included 10 or more women diagnosed with International Federation of Gynecology and Obstetrics stage 1 or higher endometrial cancer; (2) examined the diagnostic accuracy and/or clinical impact of sentinel lymph node mapping; and (3) reported outcomes measures including, but not limited to detection rate, sensitivity, negative predictive value, adverse events, treatment impact, overall survival, and/or progression-free survival.
We included all ages, tumor history, grade and stage, and all techniques and settings of sentinel node detection and dissection. We excluded studies with fewer than 10 women with endometrial cancer and meeting abstracts, reviews, case reports, or editorials. To avoid overlapping patient data in publications on the same cohort, we included the articles with the largest sample size.
After removal of duplicates using Mendeley, 2 reviewers screened titles and abstracts for initial eligibility assessment. After abstract screening, 2 reviewers reviewed full-text articles for inclusion/ exclusion. Review agreement was assessed with the kappa statistic, and disagreements were resolved by consensus.
Data extraction and quality assessment Data were extracted by 2 independent reviewers using a standardized form. These data consisted of author, year of publication, study setting, study design, patient population, SLN technique, available outcome data, adverse events, and items for quality assessment. For the SLN technique, we extracted data on surgical approach (robotic, laparoscopic, laparotomy), use of preoperative lymphoscintigraphy, injection site (cervical vs intrauterine), use of a radioactive tracer, use of indocyanine green or blue dye, and histological assessment of SLN with intraoperative frozen section or ultrastaging.
Ultrastaging was defined as any additional processing of sentinel lymph nodes beyond routine lymph node evaluation and often included additional sectioning and staining of SLNs with hematoxylin and eosin (H&E) dye; all cases using immunohistochemistry were considered to use ultrastaging. Two reviewers independently assessed the risk of bias in included studies using the QUADAS-2 tool. Differences were resolved through review of the original articles.
Because the uterus is a central organ and drains to bilateral nodal basins in the pelvis, we examined SLN detection rates by patient and by hemipelvis (defined as side-specific detection) as previously described in the literature. 6, 9 We defined the overall detection rate as the percentage of patients undergoing SLN procedures in which at least 1 sentinel node was identified on either side of an individual patient's hemipelvis and the bilateral detection rate as the percentage of patients with at least 1 sentinel node identified in each hemipelvis of an individual patient.
We defined the paraaortic detection rate as the percentage of patients undergoing SLN procedures in which at least 1 paraaortic node was identified on either side of an individual patient's hemipelvis. Occasionally nonlymphatic tissue is harvested during SLN mapping, and we excluded these nonnodal samples from SLN detection rates when reported.
We defined sensitivity as the percentage of patients with at least 1 positive SLN divided by all patients with successful lymph node detection and lymph node metastases. Given the impossibility of false-positive results (eg, any SLN with metastases is a positive node), specificity was defined as 100%.
Analysis
We used Stata 11.0 (StataCorp, College Station, TX) to conduct aggregate data random-effects meta-analyses and evaluate heterogeneity of the included studies. We calculated overall, bilateral, side-specific, and paraaortic detection rates, sensitivity, and negative predictive value estimates from data provided in the source papers. We conducted metaanalyses of detection rates using a random-effects model.
For sensitivity, we used a bivariate mixed-effects binomial regression model for the meta-analysis. 16 We used stratified bivariate meta-analyses and metaregression to explore heterogeneity in effect estimates, according to study size, patient average BMI, tumor (histology, grade), and SLN technique (surgical approach, use of preoperative lymphoscintigraphy, injection site, radioactive tracer, use of dye and radioactive tracer, indocyanine green dye usage, intraoperative frozen section) characteristics. When studies reported results for multiple subgroups (eg, comparing dyes), we included the total rate in the main metaanalysis and the subgroup rates in the stratified meta-analyses and metaregressions.
We assessed heterogeneity among the studies using the I 2 statistic and visual inspection of funnel plots.
Results
Of the 1230 abstracts screened, 55 articles including 4915 women with endometrial cancer were eligible for inclusion ( Figure 1) . 11, 12, The kappa statistic for interrater reliability was 96%. Twenty-one studies were conducted in North America, 23 in Europe, 6 in the Middle East, 3 in Asia, and 2 in South America (Table 2) . Most studies included SLN mapping followed by completion pelvic LND with or without paraaortic LND for high-grade or nonendometrioid histology endometrial cancer as the comparison. The majority of studies were prospective (87%) with consecutive patient enrollment (87%) (Appendix Table 1 ). performed by laparotomy (95% CI, 28e56), 41% by laparoscopy (95% CI, 27e54), and 17% with robotic assistance (95% CI, 7e28). Forty-four percent of SLN cases used dye alone to detect SLNs (95% CI, 30e57), 44% used a dye and a radiotracer (95% CI, 30e57), and 12% used a radiotracer alone (95% CI, 4e22). When dye was utilized, a blue dye was used more frequently than indocyanine Systematic Reviews ajog.org green (88% vs 12%), and patent blue was the most common blue dye used. Most studies used cervical injection techniques for dye and/or radiotracer distribution (58%, 95% CI, 44e71), 9% used cervical and uterine injection (95% CI, 1e17), and 33% used uterine injection alone (95% CI, 23e51).
SLN detection rates
The SLN detection rate ranged from 23% to 100%, with a pooled average of 81% (95% CI, 77e84, 53 studies) (Figure 2 ). The bilateral detection rate ranged from 6% to 88%, with a pooled average of 50% (95% CI, 44e56, 36 studies) (Figure 3 ). The side-specific detection rate ranged from 25% to 92%, with a pooled average of 66% (95% CI, 62e70, 36 studies). The paraaortic detection rate ranged from 0% to 84%, with a pooled average of 17% (95% CI, 11e23, 41 studies) (Figure 4 ). The mean number of SLNs detected per mapped patient was 2.9 (95% CI, 2.5e3.3, range, 1e8, 49 studies).
Factors associated with SLN detection rates Nonendometrioid histology (eg, serous, carcinosarcoma, and clear cell) was not associated with any significant differences in SLN detection compared with endometrioid histology (P ¼ .515) (Table 3) . Additionally, study size, average patient BMI 30 kg/m 2 , tumor grade, and surgical approach were not significantly associated with detection rates. Cervical injection was associated with significantly higher rates of ajog.org Systematic Reviews bilateral SLN detection (56% vs 33%, P ¼ .003) compared with uterine injection. However, cervical injection was associated with a significantly lower rate of paraaortic SLN detection than uterine injection (7% vs 27%, P ¼ .001). Use of indocyanine green was associated with higher rates of bilateral SLN detection (75% vs 51%, P ¼ .008) than blue dye. Preoperative lymphoscintigraphy and combined use of a radiotracer and dye were associated with higher rates of overall SLN detection (86% vs 76%, P ¼ .016, and 87% vs 78%, P ¼ .008, respectively) but showed no significant difference in rates of bilateral or paraaortic SLN detection.
SLN diagnostic accuracy
The pooled sensitivity of sentinel lymph node detection of metastatic disease was 96% (95% CI, 93e98, 47 studies) ( Figure 5 ). The pooled negative predictive value was 99.7%. In cases with SLN metastases, SLNs were the only positive nodes identified 66% of the time (22 studies).
In cases with positive SLNs, these were macrometastases in 29%, micrometastases in 39%, and isolated tumor cells in 32% of cases (14 studies). There was no significant difference in the sensitivity of SLN detection of metastases by study size, preoperative lymphoscintigraphy, injection site, radiotracer and/or dye used, intraoperative frozen section, or use of ultrastaging (Appendix Table 2 ). One study reported lower blood loss with SLN mapping compared with LND. 52 In the 24 studies reporting on adverse events (n ¼ 1390 women), 1 patient had an anaphylactic reaction to the blue dye 34 ; no other serious adverse events related to SLN mapping were reported. (Table 4) . 24, 35, 65, 69, 70 The sole study in which adjuvant therapy use did not increase with the performance of SLN mapping was in patients with uterine carcinosarcoma.
Three of 3 studies with a median follow-up of 17e50 months found no difference in the progression-free survival between patients with successful and failed SLN mapping. 65, 69, 70 Three of 3 studies with a median follow-up of 16e32 months found no difference in the progression-free survival for patients who underwent SLN mapping compared with patients who underwent primary LND. 24, 33, 53, 71 Comment In this systematic review and metaanalysis of 55 studies including 4915 women investigating the utility of SLN mapping for endometrial cancer, the following 3 primary findings emerged: (1) the pooled overall SLN detection rates were relatively high at 81% (95% CI, 77e84) with 51% (95% CI, 45e54) bilateral nodal detection; (2) the pooled sensitivity of SLN mapping for the Systematic Reviews ajog.org detection of lymphatic metastases was high at 96% (95% CI, 92e98); (3) and the use of cervical injection with combination blue dye and radiotracer or indocyanine green dye alone increased the overall SLN detection rate. Notably, we identified a higher pooled detection rate and a higher pooled sensitivity for the detection of lymphatic metastases than in prior metaanalyses. 9, 14, 72 Our analysis suggests that the SLN detection rate and sensitivity in endometrial cancer approaches those observed in breast cancer and melanoma, malignancies in which SLN mapping is the standard of care. 7 These improvements may reflect gynecological surgeons' growing experience with SLN mapping and increased utilization of more innovative dye and detection techniques.
Additionally, these data provide the rationale to consider SLN mapping as an alternative standard of care in select SLN mapping with indocyanine green demonstrated high rates of bilateral mapping. 73, 74 Given that other dye types and the combination of dye and radiotracer demonstrated high overall SLN detection rates but did not significantly improve bilateral mapping rates, indocyanine green could be considered as the preferred mapping agent for SLN mapping of endometrial cancer.
Additionally, the use of indocyanine green has several advantages compared with radiocolloids, including less pain with injection, lower cost, fewer adverse effects, and quick transcutaneous realtime visualization. 15, 73 Preoperative lymphoscintigraphy did not significantly increase bilateral or paraaortic detection rates, but there were a variety of methods (eg, different radiotracers and imaging modalities) and time delays used. Further research is needed to explore the possible benefits of preoperative lymphoscintigraphy in surgical planning for endometrial cancer, especially given the potential costs of this technique.
Cervical injection increased bilateral SLN detection rates, but we did not observe that cervical injection increases paraaortic detection as suggested in a prior review. 10 This, however, may not have a substantial impact on patient outcomes. Whereas paraaortic metastases are a poor prognostic indicator, the incidence of paraaortic metastases in the absence of pelvic metastases is exceedingly low (1e5%), especially in women with low-grade endometrial cancer. If paraaortic SLN mapping fails, pelvic SLN mapping is likely sufficient in most patients, given the low likelihood of isolated paraaortic metastases in this setting.
Interestingly, we did not identify a significant difference in sensitivity of SLN mapping with ultrastaging, despite the large number of studies (n ¼ 44) utilizing this nodal evaluation technique. This may reflect the limited experience and lack of uniform ultrastaging guidelines in endometrial cancer. Alternatively, the studies included in our meta-analysis may not be powered to ascertain the impact of ultrastaging of SLNs. Because ultrastaging is a costly and time-consuming lymphatic assessment strategy, further research is needed regarding the value of this approach and the impact of the micrometastases and isolated tumor cells identified through ultrastaging on endometrial cancer prognosis. 75 The controversy surrounding the value of ultrastaging in endometrial cancer reflects the broader uncertainty regarding the value of lymphatic assessment in endometrial cancer. Although prospective randomized trial data demonstrate the limited impact of lymphadenectomy on survival, retrospective data suggest a therapeutic benefit of lymphadenectomy in high-risk patients. 3, 4 As such, the true value of SLN mapping may be to allow the tailoring of adjuvant therapy for high-risk patients while also minimizing the risk of harm that occurs with full lymphadenectomy.
Given remaining uncertainties, the assessment of lymph nodes continues to be an important aspect of surgical staging in select women with endometrial cancer and is recognized by the National Comprehensive Cancer Network as a procedure that provides important prognostic information that may alter adjuvant treatment decisions. 13 Our data showed that SLN mapping led to upstaging of a number of women and helped tailor the subsequent receipt of additional therapy, such as chemotherapy and/or radiation, known to improve survival. 4 We were underpowered to detect any differences in survival associated with SLN vs other strategies of lymph node assessment.
Strengths and limitations
Our systematic review and meta-analysis has limitations. We excluded nonEnglish studies. We did not have individual patient data with which to analyze the impact of BMI, which may have biased BMI results toward the null. We found evidence of a significant smallstudy effect within our meta-analyses and in publication bias (data available on request). Nonetheless, although there was substantial variation between studies, this heterogeneity was largely explained by the SLN mapping variables that were included and controlled for in our meta-regressions.
Finally, an area of great interest that is notably absent from the reviewed literature is the lymphedema risk in women with endometrial cancer who undergo SLN mapping. Lymphedema rates after complete pelvic and aortic LND may be as high as 20% in this setting.
One of the potential advantages of SLN mapping is the reduced disruption of lymphatic channels compared with more comprehensive lymphadenectomy. In the breast cancer literature, replacing axillary lymphadenectomy with SLN mapping resulted in a two thirds reduction in the risk of lymphedema in the affected extremity. 7 Future studies on SLN mapping in endometrial cancer should consider assessment of lymphedema in the postoperative and surveillance periods. We await the results of a prospective trial evaluating the baseline lymphedema risk with lymphadenectomy in endometrial cancer (https://clinicaltrials.gov/ct2/show/ NCT00956670).
Conclusions and implications
In this contemporary systematic review and meta-analysis of 55 studies, sentinel lymph node mapping successfully identified nodal metastases in the vast majority of the women with endometrial cancer, with high sensitivity for the detection of lymphatic metastases. Cervical injection techniques and the use of indocyanine green dye likely increase bilateral sentinel node detection rates. Sentinel lymph node mapping is emerging as an alternative standard of care in the staging and management of select women with endometrial cancer. 
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